FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma

Web Exclusives - FDA Approvals, Lymphoma, Select Drug Profiles

On February 5, 2021, the FDA approved lisocabtagene maraleucel (Breyanzi; Juno Therapeutics), a new CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) after ≥2 previous lines of systemic therapy. The FDA granted lisocabtagene maraleucel priority review, as well as breakthrough therapy, orphan drug, and regenerative medicine advanced therapy designations.

“Today’s approval represents another milestone in the rapidly progressing field of gene therapy by providing an additional treatment option for adults with certain types of cancer affecting the blood, bone marrow, and lymph nodes,” said Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research.

This approval was based on data from the single-arm, open-label, multicenter TRANSCEND clinical trial of 192 adults with relapsed or refractory LBCL who had received lymphodepleting chemotherapy and ≥2 lines of therapy.

The overall response rate was 73% (95% confidence interval [CI], 67-80), including 54% (N = 104) complete responses (95% CI, 47-61). The median time to first response was 1 month. Of those who had a complete response, the duration of response (DOR) was ≥6 months in 65% and ≥9 months in 62%. The median DOR was 1.4 months in the patients with a partial response and was not reached in those with complete responses (95% CI, 16.7-not reached).

The most common (46%) adverse event was cytokine release syndrome (CRS), and 35% of all patients had a neurologic adverse event (grade ≥3, 12%), including 3 fatal cases. Other grade ≥3 adverse reactions included cytopenia (31%) and infection (19%). Because lisocabtagene maraleucel is associated with a risk for life-threatening CRS and other neurologic effects, the drug is only available through a REMS program.

Related Items
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
Web Exclusives published on November 30, 2022 in FDA Approvals
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
Web Exclusives published on November 17, 2022 in FDA Approvals
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
Web Exclusives published on November 17, 2022 in FDA Approvals
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
Web Exclusives published on October 31, 2022 in FDA Approvals
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
Web Exclusives published on October 31, 2022 in FDA Approvals
Last modified: August 30, 2021
Copyright © Engage Healthcare Communications, LLC. All rights reserved.